Natco Pharma’s stock dropped by 5.34 percent because the company is facing a lawsuit in the United States related to a medicine called Pomalidomide.
The lawsuit was filed by Louisiana Health Service & Indemnity Company and HMO Louisiana Inc. They are suing several companies, including Celgene Corporation, Bristol Myers Squibb, Breckenridge Pharmaceutical, and Natco Pharma.
Read more: Natco Named In US Antitrust Law Suit On Cancer Drug
Back in November 2020, Natco and its marketing partner Breckenridge Pharmaceutical received approval from the US Food and Drug Administration to sell Pomalidomide capsules. They had also resolved a patent dispute with Celgene, which is now part of Bristol-Myers Squibb and sells Pomalidomide capsules in the US under the brand name Pomalyst.
Pomalidomide, similar to thalidomide, is used in combination with dexamethasone to treat multiple myeloma in patients who have undergone at least two previous treatments, including lenalidomide and a proteasome inhibitor, and have shown disease progression within 60 days of completing the last treatment.
Source: The Hindu
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI